» Articles » PMID: 36572851

The Prognostic Utility of GRACE Risk Score in Predictive Adverse Cardiovascular Outcomes in Patients with NSTEMI and Multivessel Disease

Overview
Publisher Biomed Central
Date 2022 Dec 26
PMID 36572851
Authors
Affiliations
Soon will be listed here.
Abstract

Background: GRACE risk score models are capable of predicting all-cause mortality of non-ST elevation myocardial infarction (NSTEMI) patients. However, its utility for evaluating major adverse cardiovascular events (MACE) in NSTEMI patients with multivessel disease (MVD) remains unclear.

Methods And Results: This study was designed as a retrospective cohort study that recruited patients with NSTEMI and multivessel disease between September 2013 and December 2018 in Daping Hospital, Chongqing, China. The primary outcome was a composite outcome that included all-cause mortality, recurrent angina, non-fatal myocardial infarction, coronary re-vascularization, and non-fatal strokes. Of the 827 patients with NSTEMI, 32 did not complete follow-up and 430 were excluded because of single-vessel disease. The remaining 365 NSTEMI patients with MVD had a median follow-up of 3.0 (IQR 2.6-3.3) years, 78 patients experienced outcomes. The GRACE risk score predicted the MACE (hazard ratio 1.014, 95% CI 1.006-1.021, P < 0.001). The GRACE risk score performed well in predicting all-cause mortality (c-statistic 0.72, 95% CI 0.59-0.85, P = 0.001) in MVD but was less powerful in predicting MACE (c-statistic 0.69, 95% CI 0.62-0.75, P < 0.001). When combining the GRACE risk score with the SYNTAX score, and blood urea nitrogen for predicting all-cause mortality and MACE events, the c-statistic value increased to 0.82 and 0.81 (P < 0.001).

Conclusion: In NSTEMI patients with MVD, the GRACE score showed an acceptable predictive value for all-cause mortality, but it was less powerful in predicting MACE. Blood urea nitrogen may be valuable in assessing long-term cardiovascular events in patients with MVD.

Citing Articles

Predictive factors for multivessel disease in patients with acute coronary syndrome: analysis from the CCC-ACS project in China.

He H, Wang J, Wang Y, Gu R, Sun D, Zheng L BMC Cardiovasc Disord. 2024; 24(1):617.

PMID: 39497069 PMC: 11533343. DOI: 10.1186/s12872-024-04300-4.


The Predictive Role of Cardiac Troponin Elevation Ratio Combined With Heart Function Index Model in the Prognosis of Non-ST-Segment Elevation Myocardial Infarction Patients.

Hu X, Sun X, Cheng J, Ma J Cardiol Res. 2024; 15(4):246-252.

PMID: 39205956 PMC: 11349140. DOI: 10.14740/cr1639.

References
1.
Eagle K, Lim M, Dabbous O, Pieper K, Goldberg R, Van de Werf F . A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004; 291(22):2727-33. DOI: 10.1001/jama.291.22.2727. View

2.
Baumann A, Mishra A, Worthley M, Nelson A, Psaltis P . Management of multivessel coronary artery disease in patients with non-ST-elevation myocardial infarction: a complex path to precision medicine. Ther Adv Chronic Dis. 2020; 11:2040622320938527. PMC: 7331770. DOI: 10.1177/2040622320938527. View

3.
Thuijs D, Kappetein A, Serruys P, Mohr F, Morice M, Mack M . Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019; 394(10206):1325-1334. DOI: 10.1016/S0140-6736(19)31997-X. View

4.
Safarian H, Alidoosti M, Shafiee A, Salarifar M, Poorhosseini H, Nematipour E . The SYNTAX Score Can Predict Major Adverse Cardiac Events Following Percutaneous Coronary Intervention. Heart Views. 2015; 15(4):99-105. PMC: 4348991. DOI: 10.4103/1995-705X.151081. View

5.
Virani S, Alonso A, Benjamin E, Bittencourt M, Callaway C, Carson A . Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020; 141(9):e139-e596. DOI: 10.1161/CIR.0000000000000757. View